First Calif. Zantac Cancer Trial Scheduled for Sept. 30




OAKLAND, Calif. — Trial is set to begin in a California state action in which the plaintiff alleges that Boehringer Ingelheim Pharmaceuticals failed to warn that its popular antacid Zantac (ranitidine) was contaminated with high levels of N-Nitrosodimethylamine (NDMA), a potent carcinogen, causing him to develop bladder cancer.

Jury selection will take place on Sept. 30 in the Alameda County (Calif.) Superior Court before Judge Noël Wise; the case is the first Zantac cancer case in the state to go to trial, and the first against Boehringer to involve punitive damages.

GlaxoSmithKline developed Zantac and later sold the over-the-counter …

FIRM NAMES
  • King & Spalding
  • Moore Law Group PLLC
  • Wisner Baum LLP





UPCOMING CONFERENCES




HarrisMartin’s Artificial Stone Silicosis Epidemic Litigation Conference

January 10, 2025 - Long Beach, CA
The Westin Long Beach

MORE DETAILS



HarrisMartin's MDL Conference

December 04, 2024 - New York, NY
Virgin Hotels NYC

MORE DETAILS